Skip to main content
Top
Published in: European Journal of Epidemiology 5/2007

01-05-2007

Medication use and the risk of breast cancer

Authors: Scott Davis, Dana K. Mirick

Published in: European Journal of Epidemiology | Issue 5/2007

Login to get access

Abstract

Purpose

To investigate whether the use of commonly-prescribed medications, primarily antihypertensives and antidepressants, is associated with an increased risk of breast cancer.

Methods

Participants from a population-based case-control study were re-contacted 5–8 years after the original study regarding prescription and non-prescription medication use during the 10 years prior to diagnosis. Controls (n = 647) were frequency-matched to the cases (n = 600) by 5-year age groups. Medication use information was obtained during a telephone interview, and participants were sent the questionnaire in advance to facilitate recall. Odds ratios and 95% confidence intervals were estimated using conditional logistic regression.

Results

A slightly increased risk of breast cancer was associated with use of calcium channel blockers (CCBs), but there was no trend with increasing duration or recency of use. Breast cancer risk was not associated with use of antidepressants, beta blockers, corticosteroids, or non-steroidal anti-inflammatory drugs. Results were similar when analyses were restricted to cases with localized disease.

Conclusions

These results support previous findings that CCBs may be associated with modest increases in breast cancer risk, but not findings that non-steroidal anti-inflammatory use reduces risk.
Literature
1.
go back to reference Daling JR. Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens 1996;9:713–4PubMedCrossRef Daling JR. Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens 1996;9:713–4PubMedCrossRef
2.
go back to reference Li CI, Malone KE, Weiss NS, et al. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer 2003;98(7):1504–13PubMedCrossRef Li CI, Malone KE, Weiss NS, et al. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer 2003;98(7):1504–13PubMedCrossRef
3.
go back to reference Hole DJ, Gillis CR, McCallum IR, et al. Cancer risk of hypertensive patients taking calcium antagonists. J Hypertens 1998;16:119–24PubMedCrossRef Hole DJ, Gillis CR, McCallum IR, et al. Cancer risk of hypertensive patients taking calcium antagonists. J Hypertens 1998;16:119–24PubMedCrossRef
4.
go back to reference Fitzpatrick AL, Daling JR, Furberg CD, et al. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997;80:1438–47PubMedCrossRef Fitzpatrick AL, Daling JR, Furberg CD, et al. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997;80:1438–47PubMedCrossRef
5.
go back to reference Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493–7PubMedCrossRef Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493–7PubMedCrossRef
6.
go back to reference Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000;160:349–53PubMedCrossRef Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000;160:349–53PubMedCrossRef
7.
go back to reference Sorensen HT, Olsen JH, Mellemkjaer L, et al. Cancer risk and mortality in users of calcium channel blockers: a cohort study. Cancer 2000;89:165–70PubMedCrossRef Sorensen HT, Olsen JH, Mellemkjaer L, et al. Cancer risk and mortality in users of calcium channel blockers: a cohort study. Cancer 2000;89:165–70PubMedCrossRef
8.
go back to reference Michels KB, Rosner BA, Walker AM, et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the Nurses’ Health Study. Cancer 1998;83:2003–7PubMedCrossRef Michels KB, Rosner BA, Walker AM, et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the Nurses’ Health Study. Cancer 1998;83:2003–7PubMedCrossRef
9.
go back to reference Rosenberg L, Rao RS, Palmer JR, et al. Calcium channel blockers and the risk of cancer. JAMA 1998;279:1000–4PubMedCrossRef Rosenberg L, Rao RS, Palmer JR, et al. Calcium channel blockers and the risk of cancer. JAMA 1998;279:1000–4PubMedCrossRef
10.
go back to reference Jick H, Jick S, Derby LE, et al. Calcium-channel blockers and risk of cancer. Lancet 1997;349:525–8PubMedCrossRef Jick H, Jick S, Derby LE, et al. Calcium-channel blockers and risk of cancer. Lancet 1997;349:525–8PubMedCrossRef
11.
go back to reference Olsen JH, Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997;29:1091–4PubMed Olsen JH, Sorensen HT, Friis S, et al. Cancer risk in users of calcium channel blockers. Hypertension 1997;29:1091–4PubMed
12.
go back to reference Brandes LJ, Arron RJ, Bogdanovic RP, et al. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 1992;52:3796–800PubMed Brandes LJ, Arron RJ, Bogdanovic RP, et al. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 1992;52:3796–800PubMed
13.
go back to reference Turkington RW. Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Arch Intern Med 1972;130:349–54PubMedCrossRef Turkington RW. Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Arch Intern Med 1972;130:349–54PubMedCrossRef
14.
go back to reference Krulich L. The effect of a serotonin uptake inhibitor (Lilly 110140) on the secretion of prolactin in the rat. Life Sci 1975 17:1141–4PubMedCrossRef Krulich L. The effect of a serotonin uptake inhibitor (Lilly 110140) on the secretion of prolactin in the rat. Life Sci 1975 17:1141–4PubMedCrossRef
15.
go back to reference Steingart A, Cotterchio M, Kreiger N, Sloan M. Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 2003;32(6):961–6PubMedCrossRef Steingart A, Cotterchio M, Kreiger N, Sloan M. Antidepressant medication use and breast cancer risk: a case-control study. Int J Epidemiol 2003;32(6):961–6PubMedCrossRef
16.
go back to reference Sharpe CR, Collet J-P, Belzile E, et al. The effects of tricyclic antidepressants on breast cancer risk. Br J Cancer 2002;86:92–7PubMedCrossRef Sharpe CR, Collet J-P, Belzile E, et al. The effects of tricyclic antidepressants on breast cancer risk. Br J Cancer 2002;86:92–7PubMedCrossRef
17.
go back to reference Cotterchio M, Kreiger N, Darlington G, Steingart A. Antidepressant medication use and breast cancer risk. Am J Epidemiol 2000;151(10):951–7PubMed Cotterchio M, Kreiger N, Darlington G, Steingart A. Antidepressant medication use and breast cancer risk. Am J Epidemiol 2000;151(10):951–7PubMed
18.
go back to reference Kato I, Zeleniuch-Jacquotte A, Toniolo PG, et al. Psychotropic medication use and risk of hormone-related cancers: The New York University Women’s Health Study. J Pub Health Med 2000;22:155–60CrossRef Kato I, Zeleniuch-Jacquotte A, Toniolo PG, et al. Psychotropic medication use and risk of hormone-related cancers: The New York University Women’s Health Study. J Pub Health Med 2000;22:155–60CrossRef
19.
go back to reference Haque R, Enger SM, Chen W, Petitti DB. Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett 2005;221(1):61–5PubMedCrossRef Haque R, Enger SM, Chen W, Petitti DB. Breast cancer risk in a large cohort of female antidepressant medication users. Cancer Lett 2005;221(1):61–5PubMedCrossRef
20.
go back to reference Wang PS, Walker AM, Tsuang MT, et al. Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 2001;54:728–34PubMedCrossRef Wang PS, Walker AM, Tsuang MT, et al. Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 2001;54:728–34PubMedCrossRef
21.
go back to reference Kelly JP, Rosenberg L, Palmer JR, et al. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 1999;150:861–8PubMed Kelly JP, Rosenberg L, Palmer JR, et al. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 1999;150:861–8PubMed
22.
go back to reference Lawler DA, Juni P, Ebrahim S, Egger M. Systematic Review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J Clin Epidemiol 2003;56(2):155–63CrossRef Lawler DA, Juni P, Ebrahim S, Egger M. Systematic Review of the epidemiologic and trial evidence of an association between antidepressant medication and breast cancer. J Clin Epidemiol 2003;56(2):155–63CrossRef
23.
go back to reference Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology 2005;68(1):40–7PubMedCrossRef Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology 2005;68(1):40–7PubMedCrossRef
24.
go back to reference Garcia Rodriguez LA, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 2004;91(3):525–9PubMedCrossRef Garcia Rodriguez LA, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 2004;91(3):525–9PubMedCrossRef
25.
go back to reference Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004;291(20):2433–40PubMedCrossRef Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004;291(20):2433–40PubMedCrossRef
26.
go back to reference Moorman PG, Grubber JM, Millikan RC, Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003;14(10):915–22PubMedCrossRef Moorman PG, Grubber JM, Millikan RC, Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003;14(10):915–22PubMedCrossRef
27.
go back to reference Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11(12):1586–91PubMed Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11(12):1586–91PubMed
28.
go back to reference Jacobs EJ, Thun MJ, Connell CJ, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2005;14(1):261–4PubMed Jacobs EJ, Thun MJ, Connell CJ, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2005;14(1):261–4PubMed
29.
go back to reference Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2001;93(20):1557–62PubMedCrossRef Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2001;93(20):1557–62PubMedCrossRef
30.
go back to reference Davis S, Mirick DK, Stevens RG. Residential magnetic fields and the risk of breast cancer. Am J Epidemiol 2002;155(5):455–62CrossRef Davis S, Mirick DK, Stevens RG. Residential magnetic fields and the risk of breast cancer. Am J Epidemiol 2002;155(5):455–62CrossRef
31.
go back to reference Davis S, Kaune WT, Mirick DK, et al. Residential magnetic fields, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in women. Am J Epidemiol 2001;154(7):591–600PubMedCrossRef Davis S, Kaune WT, Mirick DK, et al. Residential magnetic fields, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in women. Am J Epidemiol 2001;154(7):591–600PubMedCrossRef
32.
go back to reference Breslow NE, Day NE. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. International Agency for Research on Cancer, 1980. (IARC Scientific Publication no. 32) Breslow NE, Day NE. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. International Agency for Research on Cancer, 1980. (IARC Scientific Publication no. 32)
33.
go back to reference Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol 2004;159(3):308–17PubMedCrossRef Boudreau DM, Daling JR, Malone KE, Gardner JS, Blough DK, Heckbert SR. A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol 2004;159(3):308–17PubMedCrossRef
Metadata
Title
Medication use and the risk of breast cancer
Authors
Scott Davis
Dana K. Mirick
Publication date
01-05-2007
Publisher
Kluwer Academic Publishers
Published in
European Journal of Epidemiology / Issue 5/2007
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-007-9135-0

Other articles of this Issue 5/2007

European Journal of Epidemiology 5/2007 Go to the issue